Effects of Oral Chondroitin Sulfate on Osteoarthritis-Related Pain and Joint Structural Changes: Systematic Review and Meta-Analysis

Knapik, Joseph J.; Pope, Rodney; Hoedebecke, Sally S; Schram, Ben; Orr, Rob Marc

doi:10.55460/jlss-pg9b

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systematic reviews of randomised clinical trials indicated that oral consumption of the joint health products chondroitin and glucosamine reduced osteoarthritis-related pain but had little or no effect on structural changes (e.g. joint space narrowing and cartilage volume) (115)(116)(117)(118)(119) .…”

Section: Osteoarthritismentioning

confidence: 99%

Associations between clinically diagnosed medical conditions and dietary supplement use: the US military dietary supplement use study

Knapik

Trone²,

Steelman³

et al. 2023

Public Health Nutr.

Self Cite

View full text Add to dashboard Cite

Objective: This study examined associations between multiple dietary supplement (DS) categories and medical conditions diagnosed by health professionals. Design: Cross-sectional. Participants: A stratified random sample of United States service members (SMs) from all military services (n=26,680). Setting: Volunteers completed an on-line questionnaire on DS use and demographic/lifestyle factors. Medical diagnoses were obtained from a comprehensive military electronic medical surveillance system and grouped into 24 clinically-diagnosed medical conditions (CDMCs). Results: After adjustment for demographic/lifestyle factors (logistic regression), higher risk was found for 92% (22/24) of CDMCs among individual vitamins/minerals users, 58% (14/24) of CDMCs among herbal users, 50% (12/24) of CDMCs among any DS users, and 46% (11/24) of CDMCs among multivitamins/multiminerals (MVM) users. Among protein/amino acid (AA) users, risk was lower in 25% (6/24) of CDMCs. For combination products, risk was higher in 13% (3/24) of CDMCs and lower in 8% (2/24). The greater the number of CDMCs, the higher the prevalence of DS use in most DS categories except proteins/AA where prevalence decreased. Conclusions: Users in many DS categories had a greater number of CDMCs, but protein/AA users had fewer CDMCs; results for combination products were mixed. These data indicate those with certain CDMCs were also users in some DS categories, especially individual vitamins/minerals, herbals, and MVM. Data are consistent with the use of DSs to enhance health, especially in those with CDMCs. Protein/AA and combination product users were more likely to be younger, more physically active men, factors that likely reduced CDMCs.

show abstract

Section: Osteoarthritismentioning

confidence: 99%

Associations between clinically diagnosed medical conditions and dietary supplement use: the US military dietary supplement use study

Knapik

Trone²,

Steelman³

et al. 2023

Public Health Nutr.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Günümüzde klinik çalışmalarda kondroitin sülfatın etkin bir şekilde tedavide yer alması için günlük 800 mg-1200 mg arasında önerilmektedir. [1,5,16] Kondroitin sülfat, kıkırdak üzerindeki anabolik ve antienflamatuvar etkilerini MMP-13, IL-1b (Interlökin-1b), ADAMTS-4 (A disintegrin and metalloproteinase with thrombospondin motifs-4), ADAMTS-5 (A disintegrin and metalloproteinase with thrombospondin motifs-5) ekspresyonlarını azaltıp seviyelerini düşürerek kondrosit apoptozu baskılayarak ayrıca hiyalüronik asit üretimini, tip II kollajen ve proteoglikan sentezini arttırarak gösterir. [17] TLR4 (Toll Like Receptor 4), CD44 (Cluster of Differentiation 44) ve ICAM1 (Intercellular Adhesion Molecule 1)'e bağlanarak kondral hasar sonrası kronikleşecek enflamasyonu baskılar.…”

Section: Glukozamin Sülfatunclassified

Oral drugs used in cartilage lesions

Bayram¹

2023

TOTBİD Dergisi

View full text Add to dashboard Cite

“…This was already demonstrated in the 2015 Cochrane review [ 48 ], which revealed that CS was better than placebo at improving pain and quality of life in patients with OA. Another meta-analysis published in 2019 [ 49 ] concluded that CS had small to moderate effectiveness in reducing OA-related pain, with larger dosages (1200 mg/d) having greater benefits than smaller dosages. However, this meta-analysis concluded that CS had only a minimal effect on joint space narrowing and no effect on cartilage volume.…”

Section: Reviewmentioning

confidence: 99%

“…However, the optimal duration of treatment and CS dosage are still uncertain, although a meta-analysis concluded that larger dosages of 1200 mg/d appear to have more benefit than lower dosages [ 48 ]. In regard to stopping OA progression, evidence has been conflicting [ 18 , 49 , 50 , 52 ], and there is still a need for further investigation to establish CS efficacy as a DMOAD.…”

Section: Reviewmentioning

confidence: 99%

Chondroitin Sulfate Supplements for Osteoarthritis: A Critical Review

Brito¹,

Costa²,

Dias³

et al. 2023

Cureus

View full text Add to dashboard Cite

Over the years, chondroitin sulfate (CS) has been used as a slow-acting drug for the treatment of osteoarthritis, for the reduction of pain and improvement of function, and for its disease-modifying properties by limiting cartilage volume loss and joint space narrowing progression. However, there have been inconsistencies in published trials regarding clinical efficacy, with reports of a lack of significant effects compared to placebo. The therapeutic effects of chondroitin sulfate may depend on many variables, such as the source of origin, purity, and contamination with by-products. Another source of confusion may be related to the fact that CS is commonly combined with glucosamine, which makes it challenging to isolate the specific contribution of chondroitin to the therapeutic outcome. This is aggravated by the fact that CS supplements, used in many countries, are not regulated, and labels wrongly claim high levels of purity. Many of these inferior CS products may have been used in clinical trials, which may have had limited but significant results. This has led to recent recommendations to opt for higher-purity pharmacologic-grade CS for the treatment of OA. This article aims to provide an up-to-date view of the current literature regarding the biological effects and efficacy of CS and discusses the quality of available chondroitin sulfate supplements and the current direction in CS investigation. This review concludes that pharmacologic-grade CS supplements may have clinically significant benefits when properly standardized; however, high-quality evidence from properly designed clinical trials is still needed to draw definitive conclusions about clinical efficacy in osteoarthritis.

show abstract

Effects of Oral Chondroitin Sulfate on Osteoarthritis-Related Pain and Joint Structural Changes: Systematic Review and Meta-Analysis

Cited by 9 publications

References 0 publications

Associations between clinically diagnosed medical conditions and dietary supplement use: the US military dietary supplement use study

Associations between clinically diagnosed medical conditions and dietary supplement use: the US military dietary supplement use study

Oral drugs used in cartilage lesions

Chondroitin Sulfate Supplements for Osteoarthritis: A Critical Review

Contact Info

Product

Resources

About